Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Roth Capital

Dianthus Therapeutics (NASDAQ:DNTH) was upgraded by research analysts at Roth Capital to a “strong-buy” rating in a research report issued on Monday, Zacks reports.

A number of other analysts have also recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $158.00 target price on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Citigroup started coverage on Dianthus Therapeutics in a report on Friday, September 4th. They issued a “buy” rating and a $156.00 target price for the company. Wedbush upped their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Raymond James Financial restated a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $128.54.

Dianthus Therapeutics Trading Up 0.2%

Shares of NASDAQ:DNTH opened at $79.52 on Monday. Dianthus Therapeutics has a 12 month low of $32.28 and a 12 month high of $117.88. The company’s fifty day moving average price is $94.59 and its 200 day moving average price is $83.94.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. On average, analysts anticipate that Dianthus Therapeutics will post -3.81 EPS for the current fiscal year.

Insider Activity

In related news, SVP Adam Veness sold 16,167 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the transaction, the senior vice president owned 3,833 shares of the company’s stock, valued at $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 23,124 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at $425,640. This trade represents a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 242,429 shares of company stock valued at $26,118,913. Insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DNTH. BlackRock Inc. purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $401,990,000. Wellington Management Group LLP raised its stake in shares of Dianthus Therapeutics by 24.4% during the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after purchasing an additional 634,099 shares during the last quarter. ABS Investment Management LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $194,960,000. Assenagon Asset Management S.A. lifted its holdings in shares of Dianthus Therapeutics by 160.9% during the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock worth $64,474,000 after purchasing an additional 451,597 shares during the period. Finally, Jennison Associates LLC acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth $40,713,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.